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Abstract
Rationale: Several studies suggest that nasal nitric oxide (nNO)
measurement could be a test for primary ciliary dyskinesia (PCD), but the
procedure and interpretation have not been standardized.
Objectives:Touseastandardprotocol formeasuringnNOtoestablishadisease-
specific cutoff value at one site, and then validate at six other sites.
Methods: At the lead site, nNO was prospectively measured in individuals
later confirmed to have PCD by ciliary ultrastructural defects (n = 143) or
DNAH11 mutations (n = 6); and in 78 healthy and 146 disease control
subjects, including individuals with asthma (n = 37), cystic fibrosis (n = 77),
and chronic obstructive pulmonary disease (n = 32). A disease-specific cutoff
value was determined, using generalized estimating equations (GEEs). Six
other sites prospectively measured nNO in 155 consecutive individuals
enrolled for evaluation for possible PCD.
Measurements andMain Results: At the lead site, nNO values in PCD
(mean6 standard deviation, 20.76 24.1 nl/min; range, 1.5–207.3 nl/min) only
rarely overlapped with the nNO values of healthy control subjects (304.66
118.8; 125.5–867.0 nl/min), asthma (267.86 103.2; 125.0–589.7 nl/min), or
chronic obstructive pulmonary disease (223.76 87.1; 109.7–449.1 nl/min);
however, therewasoverlapwith cysticfibrosis (134.06 73.5; 15.6–386.1nl/min).
The disease-specific nNO cutoff value was defined at 77 nl/minute (sensitivity,
0.98; specificity,.0.999). At six other sites, this cutoff identified 70 of the
71 (98.6%) participants with confirmed PCD.
Conclusions: Using a standardized protocol in multicenter studies, nNO
measurement accurately identifies individuals with PCD, and supports its
usefulness as a test to support the clinical diagnosis of PCD.
Keywords: primary ciliary dyskinesia; Kartagener syndrome;
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Primary ciliary dyskinesia (PCD) is a rare,
genetically heterogeneous, autosomal
recessive disorder leading to impaired ciliary
clearance from the lower airways, middle
ear, and paranasal sinuses, and is associated
with mucus retention and chronic infections
of the respiratory tract (1, 2). Accurate
diagnosis is important to initiate early
treatment to delay onset and progression of
irreparable damage in all sites, including
bronchiectasis in the lung, which is the
major factor impacting on quality of life
and prognosis (3, 4).
The diagnosis of PCD has traditionally
been made by demonstration of ciliary
ultrastructural or functional abnormalities,
using transmission electron microscopy
(EM) or video microscopy of airway
epithelial biopsies (4, 5), although these
approaches have many limitations and are
dependent on adequate sample processing
and expertise to interpret axonemal defects
or abnormal ciliary activity (6). Genetic
testing of the 21 known genes associated
with PCD is emerging, but only a minority
of individuals can currently be identified
using commercially available tests (2). An
alternative, reproducible, and cost-effective
test would help direct appropriate
individuals to further testing and
potentially lead to earlier therapy. Studies
have suggested that nasal nitric oxide
(nNO) measurement could be a useful test
for PCD (7–12).
Most nitric oxide (NO) in exhaled air
originates from the upper airways,
predominantly from the sinuses (13, 14). In
PCD, nNO values are only 10–20% of the
average values in healthy control subjects
(6). The American Thoracic Society (ATS),
in cooperation with the European
Respiratory Society (ERS), has published
guidelines for nNO measurements, which
recommend obtaining levels while the
patient performs trained velum closure or
exhales against resistance or other
techniques to decrease dilution from the
lower airways (15). Although several studies
have demonstrated that nNO levels are
significantly lower in PCD than those
measured in healthy control subjects, these
investigations had several limitations,
including small numbers of PCD-affected
subjects and few disease control subjects,
and each of these single-site studies has
used a different NO analyzer with different
sampling flow rate and methodology, which
restricts side-by-side comparisons to assess
reproducibility at multiple sites with
different operators (7–13). Further
standardization is needed for its use as
a test to support the clinical diagnosis of
PCD.
For our study, nNO levels were
measured in subjects at least 5 years of age
by a standard operating procedure (SOP) at
one site (University of North Carolina
[UNC], Chapel Hill, NC), including
children and adults with PCD, with
documented axonemal defects in ciliary
ultrastructure; healthy control subjects; and
lung disease control subjects with asthma,
cystic fibrosis, and COPD (including
longitudinal measurements in some
subjects) to generate a disease-specific cutoff
value with 98% sensitivity. For further
validation, nNO measurements were
analyzed in individuals (>5 yr of age)
undergoing evaluation for PCD at six other
sites in North America, using the same
standardized approach with instrument-
specific SOP.
Methods
Study Sites and Subjects
Investigators in the Genetic Disorders
of Mucociliary Clearance Consortium
(GDMCC; seven geographically dispersed
sites in North America) systematically and
prospectively evaluated adults and children
for possible PCD, if they had respiratory
features suggestive of PCD, including situs
abnormalities, usually after cystic fibrosis
(CF) and immunodeficiencies had been
excluded. The evaluation included
a standardized format for clinical
information and SOPs for nNO
measurements, ciliary ultrastructural
analyses, and genetic testing for disease-
causing mutations in known PCD-
associated genes. Normal control subjects
were recruited from the UNC undergraduate
and medical campus. Disease control
subjects with asthma, CF, and COPD
were recruited from pediatric and
adult pulmonary clinics at UNC.
nNO Measurement
Studies were performed during clinical
stability with palate closure, according to
ATS/ERS guidelines (6, 15, 16) and after
prospective training in use of our SOP.
Briefly, subjects achieved palate closure by
exhaling through the mouth (20–40 s) into
a disposable resistor (cardboard cylinder
with 1-mm opening at distal end
[DirectMed Inc., Glen Cove, NY] or party
favor blowout toy with comparable
resistance), while nasal gas was aspirated
through a line with a disposable foam olive
inserted into one nostril. All studies were
performed on subjects during clinically
stable periods, free of acute upper or
lower respiratory illnesses or nasal
instrumentation for at least 2 weeks before
undergoing measurements. NO was
measured with a chemiluminescence
analyzer (Sievers 280i NOA [Sievers,
Boulder, CO], CLD 88SP [ECO PHYSICS
AG, Duernten, Switzerland], or NIOX Flex
[Aerocrine AB, Solna, Sweden]) using SOPs
with two sections—“Operation of
Instrument” with details about calibration
and settings specific for the instrument
used and “Measurement Procedure,” which
was the same for all three instruments.
Criteria for an acceptable maneuver
included a greater than 20-second
exhalation with steady NO signal plateau
for 3–10 seconds on the online display.
Then, two or three reproducible maneuvers
(with less than 10% difference) were used to
calculate the mean value for each nostril.
The value for each participant was the
mean of the right and left nostril values.
nNO production (nl/min) was calculated by
multiplying nNO concentration (parts per
billion) by the sampling flow rate (0.5, 0.33,
and 0.3 L/min for the Sievers, CLD, and
NIOX, respectively). Measurements on
different analyzers at the same visit in
a subset of participants had comparable
values after adjusting for different sampling
flow rates (see Figure E1 in the online
supplement).
Other Tests
Nasal ciliated cells obtained by nasal
curettage were placed in fixative and
shipped to UNC for transmission EM and
examined for PCD-specific ultrastructural
abnormalities as described, including (1)
absent or truncated outer dynein arms
(ODA), (2) absent ODA plus absent inner
dynein arms (IDA), and (3) absent IDAs
coupled with microtubular disorganization
(7, 17, 18). An isolated IDA defect was not
diagnostic, as this can be nonspecific (19).
PCD was confirmed by identification of
biallelic DNAH11 mutations in patients
with normal ultrastructure (20). Data were
entered in a web-based Data Management
Coordinating Center (Director, J. Krischer),
including laterality defects and clinical
features. A respiratory symptom score (0 to 4)
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was calculated by assigning one point for
clinical features seen in patients with PCD
more than 5 years of age: (1) history of
unexplained neonatal respiratory distress,
(2) year-round nasal congestion, (3) year-
round wet cough, and (4) more than five
episodes of otitis media by age 2 years. For
nNO validation studies at six (non-UNC)
sites, PCD was confirmed by PCD-specific
ciliary EM defects and, by the presence of
biallelic mutations in PCD genes (20–31).
Informed consent was obtained at the
University of North Carolina at Chapel Hill
and collaborating institutions under the
auspices of Committees on the Protection
of the Rights of Human Subjects.
Statistical Methods
Generalized estimating equation (GEE)
methodology (32) was applied to fit
prediction equations for nNO measurements
(loge nNO) as a function of age, as
detailed in the online supplement.
The cutoff value was computed as the
98th percentile of the normal distribution
with mean and standard error estimated
under the GEE model. Model-based
parameter estimates were used to compute
positive and negative predictive values and
specificity, assuming three different
population prevalences of PCD in pulmonary
specialty clinics (1 in 150, 1 in 50, and 1 in
20). Statistical analyses were performed with
SAS (Cary, NC) and the R language.
Results
Subjects
The demographic characteristics for the
study populations are shown in Table 1. For
the lead site (UNC), the number of nNO
measurements and summary statistics for
age, sex, and nNO level are provided for
143 patients with PCD, as confirmed by the
presence of PCD-specific ultrastructural
defects detected by transmission EM, and
78 healthy control subjects. These data
form the basis of the model fitting used to
determine the cutoff diagnostic value and to
compute specificity, positive predictive
values (PPVs), and negative predictive
values (NPVs) for the proposed nNO test.
Table 1 also summarizes the characteristics
of disease-control subjects at UNC, and the
individuals evaluated at the other sites,
which were used to evaluate the proposed
nNO test.
Development of nNO Testing at the
Lead (UNC) Site
Development of the nNO test was based on
235 nNO measurements from 143 (82
female) patients with confirmed PCD at
UNC. Ages ranged from 5.1 to 73.0 years.
Forty younger patients with PCD (age,
5.1–16.7 yr) contributed repeated
measurements to the analysis and
demonstrated excellent reproducibility
(see Figure E2). The mean nNO level was
20.0 6 19.8 nl/minute (mean 6 SD) for
patients contributing single measurements
and 21.0 6 27.5 nl/minute for patients
with multiple measurements. The average
nNO value in 78 healthy control subjects
was 304.6 6 118.8 nl/minute.
nNO production (nl/min) remained
relatively flat for the 143 patients with
PCD across the full age range studied
(Figure 1). Thus, the cutoff value to detect
disease for the proposed test was based on
an intercept-only model fit to patients
with PCD that did not include trends with
respect to age. For the 78 healthy control
subjects, nNO production increases with
age in the younger age range. The model
providing the best fit for healthy control
subjects includes separate linear slopes with
Table 1. Characteristics of study subjects
Subjects: Measurements* Age in Years† nNO (nl/min)
Total No. (No.
Females)
No. Mean (SD) (min, max) Mean (SD) (min, max)
UNC
PCD (with PCD-specific EM defect)
Subjects with cross-sectional data
only
103 (61) 103 29.3 (17.6) (5.2, 73.0) 20.0 (19.8) (1.5, 125.3)
Subjects with longitudinal data 40 (21) 132 9.0 (3.2) (5.1, 16.7) 21.0 (27.5) (1.8, 207.3)
PCD (with biallelic DNAH11
mutations)
Subjects with cross-sectional data
only
4 (2) 4 26.2 (9.2) (12.4, 31.9) 21.0 (7.4) (9.8, 24.5)
Subjects with longitudinal data 2 (2) 6 14.2 (0.3) (13.9, 14.4) 25.9 (19.4) (12.3, 65.0)
All PCD measurements at UNC 149 (86) 245 19.1 (14.8) (5.1, 73.0) 20.7 (24.1) (1.5, 207.3)
Healthy control subjects 78 (45) 78 20.9 (15.7) (5, 73.6) 304.6 (118.8) (125.5, 867.0)
Disease control subjects
Subjects with asthma 37 (16) 37 14.8 (11.5) (5.4, 53.5) 267.8 (103.2) (125.0, 589.7)
Subjects with cystic fibrosis 77 (41) 77 16.0 (9.4) (5.5, 56.0) 134.0 (73.5) (15.6, 386.1)
Subjects with COPD 32 (10) 32 61.1 (8.9) (43.2, 77.8) 223.7 (87.1) (109.7, 449.1)
Validation subgroups (non-UNC sites)
Confirmed PCD‡ 71(45) 71 23.3 (18.0) (5.1, 69.0) 19.6 (16.6) (0.66, 31.3)
Indeterminatex 84 (46) 84 31.8 (22.3) (5.5, 79.6) 216.4 (174.5) (1.8, 991.7)
Definition of abbreviations: COPD = chronic obstructive pulmonary disease; EM = electron microscopy; nNO = nasal nitric oxide; PCD = primary ciliary
dyskinesia; UNC = University of North Carolina.
*Unless otherwise noted, subjects contribute cross-sectional measurements only.
†For longitudinal data, age is summarized on the basis of age at first measurement.
‡PCD is confirmed by EM defects (n = 65) or biallelic mutations in PCD genes but indeterminate EM (n = 6).
xThese subjects were referred because of symptoms, but EM did not show hallmark ultrastructural defect in cilia.
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respect for loge age for patients aged 5 to 11
years versus patients aged 11 to 70 years
(Figure 1).
The cutoff value for nNO was
determined to be 76.9 nl/minute (equivalent
to 4.34 loge nNO). This cutoff value
provides good separation between patients
with PCD and healthy control subjects
(Figure 2) with only a few nNO levels from
younger subjects with PCD above the cutoff
value. None of the healthy control subjects
approached the cutoff value.
Table 2 provides specificity and
PPVs stratified by age at the time of the
proposed nNO test based on nNO values in
subjects with PCD and healthy control
subjects. By design, the sensitivity of the test
is 98% across all ages. Specificity increases
with age, as would be expected from
Figure 2, but is never below 99.9% across
the ages studied. PPV increases with
increasing population prevalence. For
example, at age 5 years, PPV is 88.4%
assuming a prevalence of 1 in 150, 95.9%
assuming 1 in 50, and 98.4% assuming 1 in
20. By age 9, PPV is greater than 99.0%
regardless of the underlying prevalence and
remains so across the remaining age
range. The NPV is 99.9% for the three
prevalence values considered.
Performance of Proposed nNO Test
in Other Lung Disease Groups
Evaluated at the Lead Site
The nNO screening test was applied to other
lung disease cohorts (Table 1 and Figure 3).
All of the subjects with asthma and
COPD exceeded the cutoff line, but 12% of
the patients with CF fell below the cutoff
value. All 10 measurements from six
patients with PCD with normal ciliary
ultrastructure, but a PCD diagnosis
confirmed by biallelic, disease-causing
DNAH11 mutations, had nNO levels below
the cutoff value.
Performance of Proposed nNO
Testing at Six Other Sites
Of the 155 consecutive individuals evaluated
at the six other sites, 71 (45.8%) had
confirmed PCD based on clinical features
and the presence of typical ultrastructural
anomalies, and/or biallelic mutations in
PCD genes, including 6 with genetic
diagnosis but indeterminate ultrastructure.
Of the participants with confirmed PCD,
98.6% had nNO below the cutoff value
(Figure 4). The one participant with an
nNO level (99 nl/min) above the cutoff
value had clinical features consistent with
PCD, including situs inversus totalis, and
a clinical score of 4. For this confirmed
PCD group, the prevalence of a laterality
defect (35 of 71, or 49.3%) and the
symptom scores (2.87 6 0.86; mean 6 SD)
were similar to those in 99 patients with
PCD from the lead site (49.5% and 3.04 6
0.80, respectively) (Table 3). There were 84
individuals at other sites in whom we were
unable to demonstrate EM defects or
genetic mutations (Figure 5); thus, we could
Figure 1. Scatter plot of nasal nitric oxide (nNO) values (natural log scale; nl/min) versus age for
individuals with primary ciliary dyskinesia (PCD) and healthy control subjects, using model-predicted
values and a 95% confidence band. For nNO measurements in subjects with PCD and ciliary
ultrastructure defects evaluated at the University of North Carolina site (open triangles, single
measurements; solid triangles, repeated measurements), no trends with respect to age were
observed; consequently, an intercept-only model adequately captured the variation in nNO levels. For
healthy control subjects (open circles), nNO increased with age in a nonlinear fashion; consequently,
the model that appeared to provide the best fit included separate linear slopes with respect to loge
age for subjects between 5 and 11 years and subjects older than 11 years of age.
Figure 2. Scatter plot of nasal nitric oxide (nNO) values (linear scale; nl/min) versus age for individuals
with primary ciliary dyskinesia (PCD) and healthy control subjects with nNO cutoff (same data as
in Figure 1, shown on a linear scale). All nNO values from healthy control subjects (open circles)
were well above the cutoff (77 nl/min) and most of the nNO measurements in subjects with PCD and
ciliary ultrastructure defects (open triangles, single measurements; solid triangles, repeated
measurements) were below the cutoff. The three solid triangles above the cutoff are repeated
measurements in the same individual with PCD.
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not determine whether they had PCD,
or not. Of those 84 “indeterminate” or
“undefined” individuals, 21 of 84 (25%) had
nNO levels below the cutoff (77 nl/min),
and 63 of 84 (75%) had nNO levels above
the cutoff (Figure 5). Those with nNO
values below the cutoff of 77 nl/minute (n =
21) had respiratory symptom scores similar
to those of patients with confirmed PCD at
other sites, but higher than those with nNO
values above the cutoff (n = 63) (2.48 6
0.93 vs. 1.94 6 0.93, respectively; P ,
0.027). The prevalence of laterality defects
was low in these individuals with nNO
above the cutoff of 77 nl/minute (7.9%), as
well as in those with nNO in the PCD range
(9.5%), which might not be expected;
however, the low prevalence of laterality
defects in this latter group may reflect an
enrichment of PCD mutations that are not
associated with dynein arm defects or
laterality abnormalities (see DISCUSSION).
Discussion
Measurement of nNO levels holds promise
as a test to identify patients who have PCD,
but there has been no single standardized
procedure for measurement, even though
ATS/ERS guidelines have outlined the
general methods for nNO measurements
(15). Studies that followed ATS/ERS
guidelines have used different methods to
isolate gases from the nasopharynx, some
using a prolonged breath hold that varied
from 10 to 60 seconds, and others using
a variety of palate closure maneuvers
(7–13). Moreover, most of these studies
reported results as measured nNO
concentrations (parts per billion) without
adjustment for sampling flow rate.
These studies have used different
chemiluminescent analyzers that aspirate
nasal gas at different flow rates (varying
from 200 to 500 ml/min), which can greatly
influence the measured concentration of
nNO levels, because NO concentrations in
samples are inversely related to flow rate.
Consequently, it is difficult to directly
compare data from these different studies.
In most cases, these studies have also
been limited to a single site with relatively
small numbers of individuals with PCD,
healthy control subjects, and disease control
subjects and variations in diagnostic criteria
to define PCD. Because these studies
demonstrate consistently that measured
nNO levels are markedly lower in PCD
than in healthy control subjects, several
institutions across Europe are using nNO
measurements as part of their evaluation
for PCD (4). Further standardization of
technical aspects of the measurement,
identification of specific cutoff value, and
validation of testing across multiple sites is
needed before implementing nNO levels as
an adjunctive test in selected centers to
identify individuals with PCD.
In this study, we systematically
measured nNO levels during palate closure
in a sizable number of healthy control
subjects and individuals with PCD across
a wide age range (5–73 yr old) and in
several control populations with airway
diseases (CF, asthma, and COPD). The
nNO values are reported as nNO
production (product of nNO concentration
and transnasal sampling flow rate) to
correct for the flow rate for different
Table 2. Specificity and positive predicted values of the nasal nitric oxide screening test*
Age in Years Specificity PPV (Prevalence 1/150)† PPV (Prevalence 1/50)‡ PPV (Prevalence 1/20)x
5 0.99914 0.884 0.959 0.983
11 0.99997 0.995 0.998 0.999
21 0.99998 0.996 0.999 0.999
50 0.99998 0.998 0.999 0.999
70 0.99999 0.998 0.999 0.999
Definition of abbreviations: NPV = negative predicted value; PPV = positive predicted value.
*The nasal nitric oxide cutoff value is 76.9, based on an assumed sensitivity of 0.98.
†NPV = 0.99987 over all ages.
‡NPV = 0.99959 over all ages.
xNPV = 0.99895 over all ages.
Figure 3. Scatter plot of nasal nitric oxide (nNO) values (linear scale; nl/min) versus age for University
of North Carolina disease control subjects and a subset of subjects with primary ciliary dyskinesia
(PCD) with normal electron micrographs but biallelic mutations in DNAH11. Individual nNO
measurements are shown for disease control subjects: asthma (open circles), cystic fibrosis (open
squares), and chronic obstructive pulmonary disease (solid triangles). In addition, 10 measurements
are shown for a special subset of PCD (solid circles) with PCD confirmed by the presence of
biallelic mutations in DNAH11 despite normal ultrastructure.
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analyzers. For subjects with PCD, nNO
production remains low and relatively flat
across ages. For healthy control subjects,
however, nNO increases slightly with age
for subjects 5–10 years of age, but with little
change thereafter. Because the majority
of nNO is thought to arise from the
paranasal sinuses (13, 14), the age-related
increase in nNO levels in the younger
cohort likely reflects development and
growth of paranasal sinuses. Studies have
demonstrated that nNO can be measured in
younger children during tidal breathing
(33); however, nNO values during tidal
breathing are lower than during palate
closure maneuvers. Other preliminary
studies suggest that nNO measured during
tidal breathing with a hand-held device has
promise as a diagnostic test for PCD (34).
For these other approaches, studies are
needed to standardize the protocol,
establish appropriate cutoff values, and
validate across multiple sites.
For the confirmed PCD group with
defined ultrastructural defects in the ciliary
axonemes, the mean nNO level (20.0 nl/
min) is less than 10% of the mean nNO
measurement for healthy control subjects
(304.6 nl/min) with minimal overlap.
Previous reports in smaller subsets show
a similar magnitude of difference between
PCD and healthy control subjects (7–12).
The cutoff value defined in this study
(77 nl/min) is slightly lower than what was
identified in our earlier study that
examined a smaller patient population (7).
nNO values for subjects with asthma
and COPD do not overlap with values
in PCD, and are comparable to values in
normal control subjects. The nNO values in
some of the patients with CF, however, did
overlap with PCD values, which has been
described in other studies (7–9, 11).
Therefore, CF must be excluded by
a quantitative pilocarpine iontophoresis
sweat test or CFTR genotype testing in all
individuals with nNO measurements below
the cutoff values. As newborn screening
for CF extends to more universal
application, the potential for CF
confounders should decrease, because early
diagnosis of CF will limit their referral at
older ages to specialty clinics for diagnostic
evaluation.
Using a standardized approach to
evaluate PCD, including a uniform nNO
protocol and cutoff value at six other
GDMCC clinical research sites, nNO
measurements identified virtually every
participant with confirmed PCD (defined by
the presence of a “hallmark” ultrastructural
defect of the ciliary axonemes, or biallelic
mutations in genes known to cause PCD).
All but one of the 71 individuals with
confirmed PCD had nNO values below
the cutoff.
We propose that a substantial portion
of the 21 participants at other (non-UNC)
sites without identified PCD-specific
ultrastructural defects or biallelic mutations,
but nNO levels below the cutoff value (77 nl/
min), may ultimately prove to have PCD,
based on the strong clinical phenotype and
high respiratory scores (Figure 5 and
Table 3). The lower prevalence of laterality
defects (9.5%) in these 21 individuals most
likely reflects a low prevalence of dynein
arm defects that are (more) easily defined
on ciliary ultrastructural analysis, and that
Figure 4. Validation data from six other sites: primary ciliary dyskinesia (PCD) confirmed with
ultrastructural defect or biallelic mutations in gene-associated electron microscopy (EM) defect. Single
nasal nitric oxide (nNO) measurements are shown for the six other Genetic Disorders of Mucociliary
Clearance Consortium (GDMCC) sites: National Institute of Allergy and Infectious Diseases (Bethesda,
MD; 43 participants); Washington University (Saint Louis, MO; 39 participants); Hospital for Sick
Children (Toronto, ON, Canada; 26 participants); University of Colorado (Denver, CO; 23 participants);
University of Washington (Seattle, WA; 18 participants); and Stanford University (Palo Alto, CA;
6 participants). The open circles represent individuals with PCD confirmed by identification of
ultrastructural defect. The solid circles represent individuals with PCD confirmed by genetic testing
alone, demonstrating biallelic mutations in a PCD gene.
Table 3. Laterality defect and respiratory symptoms
Prevalence of Laterality Defect Prevalence of Symptom Score ‡ 3 Symptom Score Mean 6 SD
Confirmed at lead site (n = 99) 49.5% 73.7% 3.04 6 0.80
Validation groups 49.3% 62.0%
Confirmed PCD (n = 71) 2.87 6 0.86
Indeterminate (n = 84) 9.5% 52.4% 2.48 6 0.93*
Below cutoff (n = 21)
Above cutoff (n = 63) 7.9% 27.0% 1.94 6 0.93*
Definition of abbreviation: PCD = primary ciliary dyskinesia.
*P = 0.027 by two-tailed t test.
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are associated with laterality defects in 50%
of patients. These 21 individuals likely have
a high prevalence of central apparatus
defects, which are less apparent on EM
analysis, and not associated with laterality
defects. Therefore, the confirmed PCD
group is highly enriched with dynein arm
defects that are associated with laterality
defects, whereas the undefined group has
normal dynein arms and is more likely
enriched with central apparatus defects that
are not associated with laterality defects.
The genetic basis for PCD is rapidly
emerging, and a growing number of
mutations in multiple genes that encode
proteins involved in ciliary structure,
function, and assembly have been
implicated in disease. We speculate that
many patients with nondiagnostic ciliary
ultrastructure, but a strong clinical
phenotype and low nNO levels, at the other
six sites will have mutations in PCD-
associated genes that affect the central
apparatus. Similarly, with further advances
in our understanding of PCD genes and
genotype–phenotype correlations, novel
genetic variants may emerge that are not
associated with low nNO.
As with any biological test, nNO testing
has limitations and confounders that
must be considered. Acute respiratory
infections can damage the respiratory
epithelium, resulting in lower nNO values.
Therefore, nNO levels should be measured
during periods of clinical stability and at
least 2 weeks after an acute respiratory
illness. Blood in the nasal cavity can rapidly
bind NO, so the nasal mucosa must be
examined before nNO measurements; plus,
nNO measurements should be delayed
if there has been a recent nosebleed.
Because of these potential confounders,
measurements should be repeated at least
once on a separate day to ensure that
reduced nNO levels are reproducible.
Standardized procedures must be followed
to ensure that measurements are accurate,
including routine analyzer calibration,
ambient NO level measurements,
examination of tubing for secretions in
tubing that can alter flow rate, and
monitoring flow rates.
The usefulness of the nNO test,
especially the PPV, depends on the
prevalence of PCD within the target
populations of patients that are tested. As
demonstrated in Table 2, the PPV decreases
as the prevalence of PCD within the
tested population decreases from 1 in 20 to
1 in 150, particularly in younger children.
For target populations such as those with
chronic oto-sino-pulmonary disease
starting in early childhood or those with
situs inversus totalis (in which the
prevalence of PCD is likely greater than 1 in
50), the PPV is strong (0.96 or better); but,
for other populations such as those with
recurrent otitis media or chronic cough,
in which the prevalence of PCD is much
less than 1 in 150, the PPV will be less
robust. At this point, nNO testing is not
ready for broad-scale clinical use, but we
expect it to be employed in specialized
centers that are evaluating complex patients
and therefore selecting appropriate target
populations for testing, using SOPs.
This study provides data that will be
important for applications to the U.S. Food
and Drug Administration (and other
regulatory agencies) for approval of
nNO devices for future clinical use.
Unfortunately, infants and young children
cannot cooperate with velum closure
maneuvers described in our SOP.
Preliminary studies have shown that nNO
can be measured during tidal breathing
(33); however, further standardization and
definition of disease-specific cutoff values
are needed for application of this tidal
breathing approach in very young children
to aid in early identification of PCD.
In summary, we have defined
a standardized protocol for measuring nNO
levels during palate closure in adults and
children at least 5 years of age that can be
used as a noninvasive test for PCD. In
healthy children, nNO values increase
progressively with age between 5 and
10 years of age, likely reflecting sinus
development. In PCD, nNO values remain
extremely low across all ages. The defined
nNO cutoff value has robust ability to
discriminate between “classic” forms of
PCD (confirmed only in patients with
specific ultrastructural defects and/or
biallelic mutations in selected PCD genes)
from other pulmonary conditions, with the
exception of CF. Preliminary validation
of this approach was confirmed at six other
sites, which accurately identified subjects
with PCD using the same protocol for nNO
measurement and the same cutoff value.
These results provide the basis for
a noninvasive test to support the clinical
diagnosis of PCD. n
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